Kelsee,

The Feb 8th news release stated "For 2018, the Company targets commencing enrollment of US-based patients in its Phase 3 BETonMACE trial in the first half of 2018, conducting a Sample Size Reestimation Analysis by approximately  mid-2018, completing enrollment in BETonMACE by the second quarter of 2018 based on the currently targeted 2,400 patients, and having top-line data around the end of 2018."

I read that to indicate that Resverlogix expects to conduct the SSRA anytime between that news release on Feb 8th, 2018 and mid-2018........whenever the 188th event is adjudicated. Mid-2018 is a broad term. They never stated a June 2018 SSRA release date. Could be April, May, June, July, etc.